While some studies show opioids are ineffective for pain after 12 weeks, conclusive research on the topic is limited. The FDA-mandated research will focus on all immediate, long-acting and extended-release opioids prescribed to patients for use outside of healthcare settings.
“We are going to impose a mandate on existing products … to answer the question that people have been posing for years: whether you have declining efficacy, and whether that declining efficacy can lead to addiction,” FDA Commissioner Scott Gottlieb, MD, told The Washington Post.
If the research points to opioids’ ineffectiveness, the agency could make labeling changes, implement special prescribing and dispensing rules, or even prohibit their use, according to Dr. Gottlieb.
More articles on opioids:
Purdue Pharma didn’t correct misperceptions about OxyContin strength: 5 notes
Google to tackle opioid epidemic by adding drug disposal locations to Maps
Summa Health’s chief anesthesiologist wants to eliminate opiates from surgeries
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
